Asia-Pacific Lung Transplant Therapeutics Market, By Product (Immunosuppressant Drugs, Organ Preservation Products, Tissue Products, and Others), Indication (Chronic Obstructive Pulmonary Diseases (COPD), Pulmonary Fibrosis, Septic Lung Disease, Pulmonary Hypertension, Cystic Fibrosis, Interstitial Pulmonary Fibrosis, Emphysema, Sarcoidosis, Primary Pulmonary Arterial Hypertension, and Others), Type (Cadaveric Lung Transplantation, Living Lung Transplantation), Technique (Single-Lung Transplantation, Bilateral-Lung Transplantation, Heart-Lung Transplantation, and Double Lung Transplantation), Patient Demographics (Geriatric, Adult, Paediatric), End Users (Hospital, Transplant Centres, Specialty Centres, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Vietnam, Indonesia, the Philippines, and the Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Analysis and Insights: Asia-Pacific Lung Transplant Therapeutics Market
The Asia-Pacific lung transplant therapeutics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 3.2% in the forecast period of 2022 to 2029 and is expected to reach USD 31.89 million by 2029. The launch of new products by major market players is expected to drive the market's demand in the forecast period.
A lung transplant is surgery done to remove a diseased lung and replace it with a healthy lung from another person. Lung transplants surgery can be performed on people of almost all ages, from newborns to adults up to age 65 and sometimes even later. A lung transplant is for people who have tried other medications or treatments, but their underlying conditions have not improved sufficiently or worsened over time. Depending on the patient's medical condition, a lung transplant may involve replacing one lung or both. The lungs may be transplanted with a donor's heart in some situations. A lung transplant can significantly improve patient health and quality of life.
Increasing drug approvals, rise in clinical trials, high incidence of chronic disease, and some ongoing research to increase the therapeutics application is expected to drive the market's growth. However, fewer donors for organ donation and the high cost of lung transplant procedures may hamper the market growth. Meanwhile, rising healthcare spending, strategic initiatives by market players, technological advancements in lung transplantation may create opportunities for market growth. Stringent regulatory framework and complications associated with lung transplantation may challenge the market growth.
The Asia-Pacific lung transplant therapeutics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief; our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Lung Transplant Therapeutics Market Scope and Market Size
The Asia-Pacific lung transplant therapeutics market is segmented into product, type, indication, , technique, patient demographics, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the Asia-Pacific lung transplant therapeutics market is segmented into immunosuppressant drugs, tissue products, organ preservation products, and others. In 2022, the immunosuppressant drugs segment is expected to dominate the Asia-Pacific lung transplant therapeutics market due to the use of immunosuppressant drugs to avoid lung rejection.
- On the basis of type, the Asia-Pacific lung transplant therapeutics market is segmented into cadaveric lung transplantation and living lung transplantation. In 2022, the cadaveric lung transplantation segment is expected to dominate the Asia-Pacific lung transplant therapeutics market due to increased awareness regarding organ donation and registration.
- On the basis of indication, the Asia-Pacific lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, primary pulmonary arterial hypertension sarcoidosis, and others. In 2022, the cystic fibrosis segment is expected to dominate the Asia-Pacific lung transplant therapeutics market due to the surge in the patient pool of cystic fibrosis patients.
- On the basis of technique, the Asia-Pacific lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation, and double lung transplantation. In 2022, the single-lung transplantation (SLT) segment is expected to dominate the Asia-Pacific lung transplant therapeutics market due to the surge in lung transplantation procedures.
- On the basis of patient demographics, the Asia-Pacific lung transplant therapeutics market is segmented into adult, pediatric, and geriatric. In 2022, the adult segment is expected to dominate the Asia-Pacific lung transplant therapeutics market due to the surge in health complications observed in the adult population and the rise in the waiting list of adult patients awaiting transplantation, which would determine the lung transplantation procedure.
- On the basis of end users, the Asia-Pacific lung transplant therapeutics market is segmented into hospital, transplant centers, specialty centers, and others. In 2022, the hospital segment is expected to dominate the Asia-Pacific lung transplant therapeutics market due to increased awareness regarding organ donation, registration, and chronic diseases.
Asia-Pacific Lung Transplant Therapeutics Market Country Level Analysis
The Asia-Pacific lung transplant therapeutics market is analyzed, and market size information is provided based on product, type, indication, technique, patient demographics, and end users.
Some of the countries covered in the Asia-Pacific lung transplant therapeutics market are Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Vietnam, Indonesia, the Philippines, and the Rest of Asia-Pacific.
The immunosuppressant drugs segment in the Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing clinical trials and research development to prevent chronic diseases. China is expected to lead the growth of the Asia-Pacific market due to increasing approval of drugs for transplant with a continuous increase in investments for research and development, which fuel pharmaceutical innovation. India is expected to dominate the market due to the increasing geriatric population.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Healthcare Expenditure and Chronic Diseases boost the Asia-Pacific Lung Transplant Therapeutics Market Growth
The Asia-Pacific lung transplant therapeutics market also provides you with detailed market analysis for every country's growth in the lung transplant industry with sales, the impact of advancement in the lung transplant technology, and changes in regulatory scenarios with their support for the lung transplant therapeutics market. The data is available for the historical period 2011 to 2020.
Competitive Landscape and Asia-Pacific Lung Transplant Therapeutics Market Share Analysis
The Asia-Pacific lung transplant therapeutics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points are only related to the company's focus on the Asia-Pacific lung transplant therapeutics market.
Some major manufacturers for the Asia-Pacific lung transplant therapeutics market are Apotex Inc, Bridge to Life Ltd, Intas Pharmaceuticals Ltd., Viatris Inc., Pfizer Inc., F.Hoffmann-La Roche Ltd., Panacea Biotec Ltd., Astellas Pharma Inc., Accord-UK Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Detraxi Inc, Dr. Reddy's Laboratories Ltd., among others.
Various market players provide the faster-growing healthcare segment and major technological developments in organ transplantation.
For instance,
- In April 2021, Astellas Pharma Inc. received the "2021 Award for Excellence in Corporate Disclosure" from the Securities Analysts Association of Japan. This helped company in strengthening its position over the market, gaining more customer base
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other market players enhance the company in the Asia-Pacific lung transplant therapeutics market, which also benefits the organization to improve its offering.
SKU-